Our result is the same as that from the Diabetes Reduction Assessment with Ramipril and Rosglitazone Medication (DREAM) trial [26], which failed to show a statistically significant reduction in NOD with the ACE inhibitor ramipril versus placebo in patients with IFG. Here, ACE is linked to diabetes mellitus.